Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
Primary Purpose
Colonic Neoplasms
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
XELOX or FOLFOX chemotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Colonic Neoplasms focused on measuring Colonic Neoplasms, Laparoscopic Surgery, Neoadjuvant chemotherapy, T4
Eligibility Criteria
Inclusion Criteria:
- Able to provide written informed consent
- Histologically confirmed diagnosis of colon carcinoma
- CT or MRI verified as T4 colon cancer without involvement of other organs.
- Without multiple lesions other than carcinoma in situ
- Tumor size < 8 cm
- No bowel obstruction
- Sufficient organ function
- No history of gastrointestinal surgery
- 18 years of age or older
- Performance Status (ECOG) 0, 1 or 2, life expectancy > 12 weeks
- Operable patients
- Completion of neoadjuvant systemic chemotherapy
Exclusion Criteria:
- Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding
- No intention to finish neoadjuvantive systemic therapy
- Unstable or uncompensated respiratory or cardiac disease
- Serious active infections
- Hypersensitivity to capecitabine/fluorouracil or oxaliplatin
- Stomatitis or ulceration in the mouth or gastrointestinal tract
- Severe diarrhea
- Peripheral sensory neuropathy with functional impairment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Laparoscopic surgery
Neoadjuvantive chemotherapy + Laparoscopic surgery
Arm Description
Patients with T4 colon cancer receive laparoscopic surgery only.
Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
Outcomes
Primary Outcome Measures
Disease free survival
calculated from the date of surgery to the date of recurrence
Secondary Outcome Measures
Overall survival
calculated from the date of diagnosis to the date of death from any cause
Adverse events (mortality and morbidity)
Number of participants with treatment-related adverse events assessed by CTCAE v4.0
The proportion of completion of laparoscopic surgery
The number of completion of laparoscopic surgery/the number of participants
Full Information
NCT ID
NCT02777437
First Posted
May 2, 2016
Last Updated
May 17, 2016
Sponsor
Fudan University
Collaborators
Shanghai Jiao Tong University School of Medicine, Zhejiang University, Tongji University
1. Study Identification
Unique Protocol Identification Number
NCT02777437
Brief Title
Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
Official Title
Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
October 2019 (Anticipated)
Study Completion Date
October 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fudan University
Collaborators
Shanghai Jiao Tong University School of Medicine, Zhejiang University, Tongji University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Primary Outcome Measures: Disease free survival
Secondary Outcome Measures:
Overall survival
Adverse events (Mortality, morbidity)
The proportion of completion of Laparoscopic Surgery
Estimated Enrollment: Oct, 2016
Study Start Date: Oct, 2016
Estimated Study Completion Date: Oct, 2019
Estimated Primary Completion Date: Oct, 2021
Groups/Cohorts
Laparoscopic surgery for T4 colon cancers
Neoadjuvantive chemotherapy + Laparoscopic surgery for T4 colon cancers
Detailed Description
Investigators' previous studies indicated that laparoscopic surgery is feasible in T4 colon cancers with comparable clinical and oncologic outcomes. Laparoscopy may be considered as an alternative approach for T4 colon cancers with the advantage of faster recovery. The survival outcome of T4 colon cancers still dismays clinicians and patients. Preoperative chemotherapy is an attractive concept for locally advanced colon cancer. Optimal systemic therapy at the earliest possible opportunity may be more effective at eradicating distant metastases than the same treatment given after the delay and immunological stress of surgery. Besides, the shrinkage of primary tumor before surgery may reduce the risk of incomplete surgical excision and the risk of shedding of tumor cells during surgery. The aim of the present study is to compare the short-and long-term survival outcomes between laparoscopic surgery alone and laparoscopic surgery with 4 cycles of neoadjuvant chemotherapy for T4 colon cancer as well as the mortality and the morbidity.
The number of patients, which needs to get power of 80%, is 1960. The average numbers of patients needs to reach approximately 200, and that of surgical centers needs to reach 10.
Arrangements in the preoperative, intraoperative and postoperative period will be in complete accordance with the usual care of the center.
The baseline demographics and conditions as well as the perioperative items and the postoperative occurrences will be recorded through a prior designed e-questionnaire.
Globally,the disease free survival rate (chemotherapy and surgery), mortality (chemotherapy and surgery), the morbidity (chemotherapy and surgery) and the proportion of completion of laparoscopic surgery of the two surgical strategies will be analized and compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colonic Neoplasms
Keywords
Colonic Neoplasms, Laparoscopic Surgery, Neoadjuvant chemotherapy, T4
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1960 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Laparoscopic surgery
Arm Type
No Intervention
Arm Description
Patients with T4 colon cancer receive laparoscopic surgery only.
Arm Title
Neoadjuvantive chemotherapy + Laparoscopic surgery
Arm Type
Experimental
Arm Description
Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
Intervention Type
Drug
Intervention Name(s)
XELOX or FOLFOX chemotherapy
Other Intervention Name(s)
Xeloda+ OXA or OXA+ 5-FU
Intervention Description
4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
Primary Outcome Measure Information:
Title
Disease free survival
Description
calculated from the date of surgery to the date of recurrence
Time Frame
3-year
Secondary Outcome Measure Information:
Title
Overall survival
Description
calculated from the date of diagnosis to the date of death from any cause
Time Frame
3-year
Title
Adverse events (mortality and morbidity)
Description
Number of participants with treatment-related adverse events assessed by CTCAE v4.0
Time Frame
3-month
Title
The proportion of completion of laparoscopic surgery
Description
The number of completion of laparoscopic surgery/the number of participants
Time Frame
1-month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to provide written informed consent
Histologically confirmed diagnosis of colon carcinoma
CT or MRI verified as T4 colon cancer without involvement of other organs.
Without multiple lesions other than carcinoma in situ
Tumor size < 8 cm
No bowel obstruction
Sufficient organ function
No history of gastrointestinal surgery
18 years of age or older
Performance Status (ECOG) 0, 1 or 2, life expectancy > 12 weeks
Operable patients
Completion of neoadjuvant systemic chemotherapy
Exclusion Criteria:
Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding
No intention to finish neoadjuvantive systemic therapy
Unstable or uncompensated respiratory or cardiac disease
Serious active infections
Hypersensitivity to capecitabine/fluorouracil or oxaliplatin
Stomatitis or ulceration in the mouth or gastrointestinal tract
Severe diarrhea
Peripheral sensory neuropathy with functional impairment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiong Wu, MD,PhD
Phone
0086-21-34610367
Email
18918298120@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wei Jin, MD,PhD
Phone
0086-21-64175590
Ext
25022
Email
34865893@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xinxiang Li, MD,PhD
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
We'll reach out to this number within 24 hrs